ASCO[removed]Clinical response by baseline characteristics in patients with relapsed and bortezomib-refractory multiple myeloma treated with panobinostat, bortezomib, and dexamethasone (PANORAMA 2) Melissa Alsina,1 Paul G.

First Page		Document Content
Date: 2013-06-10 19:40:25 Immunosuppressants Orphan drugs Amides Bortezomib Pyrazines Lenalidomide Multiple myeloma Dexamethasone Mantle cell lymphoma Medicine Chemistry Organic chemistry		ASCO[removed]Clinical response by baseline characteristics in patients with relapsed and bortezomib-refractory multiple myeloma treated with panobinostat, bortezomib, and dexamethasone (PANORAMA 2) Melissa Alsina,1 Paul G. Add to Reading List Source URL: myeloma.org Download Document from Source Website File Size: 408,41 KB Share Document on Facebook

	Functional disassociation of the central and peripheral fatty acid amide signaling systems Benjamin F. Cravatt†, Alan Saghatelian, Edward G. Hawkins, Angela B. Clement, Michael H. Bracey, and Aron H. Lichtman‡ DocID: 1qJmk - View Document
	doi:S1367 DocID: 1qvvT - View Document
	Biochemistry 1999, 38, 14125 Fatty Acid Amide Hydrolase Competitively Degrades Bioactive Amides and Esters through a Nonconventional Catalytic Mechanism† DocID: 1pvP1 - View Document
	SPECIAL AUTHORIZATION REQUEST DPP-4/SGLT2 INHIBITORS Fax requests toOR mail requests to PEI Pharmacare, P.O. Box 2000, Charlottetown, PE, C1A 7N8 SECTION 1 – PRESCRIBER INFORMATION DocID: 1pr3h - View Document
	Official Newsletter of the Utah Poison Control Center 2010 • VOLUME 12 • ISSUE 4 T O D A Y NEW DRUGS FOR TREATMENT OF DIABETES DocID: 1oY1K - View Document